Mutant Peptide Stabilizes Oligomers in Alzheimer's Disease
Author Information
Author(s): Rajadas Jayakumar, Corey W. Liu, Paul Novick, Nicholas W. Kelley, Mohammed Inayathullah, Melburne C. LeMieux, Vijay S. Pande
Primary Institution: Stanford University
Hypothesis
Can mutations in the Aβ42 peptide sequence stabilize oligomers in solution?
Conclusion
The Aβ42Nle35p37 mutant peptide forms stable oligomers and reduces fibril formation of the wild-type Aβ42 peptide.
Supporting Evidence
- The mutant peptide Aβ42Nle35p37 showed a significantly higher yield of soluble oligomers compared to the wild-type Aβ42.
- NMR spectroscopy revealed the occurrence of two β-turns in the mutant peptide, which may contribute to its stability.
- The Aβ42Nle35p37 mutant inhibited the aggregation of the wild-type Aβ42 peptide.
Takeaway
Scientists changed a part of a protein related to Alzheimer's disease to see if it could help it stick together better, and it worked! This might help us understand how to stop the disease.
Methodology
The study used molecular modeling, NMR spectroscopy, and other biophysical techniques to analyze the properties of the mutant peptide.
Limitations
The study did not detect known secondary structure stretches other than the two β-turns, suggesting limitations in structural characterization.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website